Balchem (Nasdaq: BCPC) reported earnings on July 31. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Balchem missed estimates on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue grew. GAAP earnings per share expanded significantly.

Margins increased across the board.

Revenue details
 Balchem tallied revenue of $83.3 million. The three analysts polled by S&P Capital IQ foresaw net sales of $86.9 million on the same basis. GAAP reported sales were 5.4% higher than the prior-year quarter's $79.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
 EPS came in at $0.38. The three earnings estimates compiled by S&P Capital IQ averaged $0.39 per share. GAAP EPS of $0.38 for Q2 were 15% higher than the prior-year quarter's $0.33 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Margin details
 For the quarter, gross margin was 29.9%, 130 basis points better than the prior-year quarter. Operating margin was 19.9%, 110 basis points better than the prior-year quarter. Net margin was 13.9%, 130 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $83.4 million. On the bottom line, the average EPS estimate is $0.39.

Next year's average estimate for revenue is $343.9 million. The average EPS estimate is $1.53.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 341 members out of 349 rating the stock outperform, and eight members rating it underperform. Among 99 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 98 give Balchem a green thumbs-up, and one give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Balchem is outperform, with an average price target of $50.67.

Looking for alternatives to Balchem? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.